摘要
肝细胞癌(HCC)是原发性肝癌(PHC)中最常见的一种类型,是一种高度异质性、复杂性和侵袭性的恶性肿瘤。目前根治性的肝切除术依旧是肝细胞癌的最主要的治疗方法,然而术后患者的生存率以及肿瘤的高复发率依旧存在很大问题。近些年来,全身免疫炎症指数(systemic immune-inflammation index)和γ-谷氨酰转肽酶/血小板比值(GPR)等已经成为HCC研究的热点问题。SII作为一种全身炎症反应的评价指标,现已被证实与HCC患者的预后相关。γ-谷氨酰转肽酶、血小板也被证实是肝细胞癌的独立危险因素。本文将从全身免疫炎症指数SII和γ-谷氨酰转肽酶/血小板比值GPR指标出发,与肝细胞癌相关联进行系统性综述,以便更好地了解相关指标在HCC患者预后中的应用和作用。
Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer (PHC). It is a highly heterogeneous, complex and aggressive malignancy. At present, radical hepatectomy is still the main treatment method for hepatocellular carcinoma;however, the survival rate of postopera-tive patients and the high recurrence rate of tumors are still a big problem. In recent years, sys-temic immunoinflammatory index and gamma-glutamyl transpeptidase/platelet ratio (GPR) have become hot topics in HCC research. SII, as an evaluation indicator of systemic inflammatory re-sponse, has been confirmed to be associated with the prognosis of HCC patients. Gamma-glutamyl transpeptidase and platelets have also been shown to be independent risk factors for hepatocellu-lar carcinoma. Based on systemic immunoinflammatory index SII and gamma-glutamyl transpep-tidase/platelet ratio GPR indicators, this paper will conduct a systematic review of their association with hepatocellular carcinoma, so as to better understand the application and role of relevant indi-cators in the prognosis of HCC patients.
出处
《临床医学进展》
2023年第7期11529-11534,共6页
Advances in Clinical Medicine
